Selank

Selank: A Scientific Review

Based on peer-reviewed literature — see References. Last updated: April 2026.

The Short Version

Selank is an unusual compound in the Western nootropic and peptide market: it is not an experimental research chemical theorised to work — it is a drug that has been clinically approved and used in Russia and Ukraine since 2009 for the very conditions people take it for. That is a meaningful distinction that separates it from most of the peptides in this series.

The backstory begins with tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) released by enzymatic cleavage of the IgG heavy chain during normal immune processing. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences extended the tuftsin sequence at the C-terminus with the tripeptide Pro-Gly-Pro, dramatically improving metabolic stability and adding CNS activity. The result was Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) — a heptapeptide with anxiolytic, nootropic, and immunomodulatory properties.

The Russian clinical trial evidence — principally the 2008 Zozulia et al. study comparing Selank to medazepam in 62 patients with GAD and neurasthenia — showed that Selank produced anxiolytic effects comparable to the benzodiazepine comparator but without sedation, dependence, or withdrawal, and with added antiasthenic and psychostimulant effects.^[1] The evidence limitations are equally real: small trials, Russian institutions only, limited independent international validation.

Derivation from Tuftsin

Tuftsin (Thr-Lys-Pro-Arg) is a naturally occurring tetrapeptide first isolated by Victor Najjar at Tufts University in 1970, produced by enzymatic cleavage of the Fc region of IgG heavy chains. Tuftsin has pro-immune properties (stimulates phagocytosis, NK cell activity, macrophage function) and documented CNS effects including anxiolytic and anti-stress properties in rodent models. Its pharmacological liability: very short plasma half-life (minutes) due to rapid degradation by aminopeptidases.

The Institute of Molecular Genetics team, led by Igor Ashmarin, addressed this by appending the tripeptide Pro-Gly-Pro to the C-terminus. This modification creates steric hindrance protecting against carboxypeptidase degradation, and the two proline residues confer resistance to endopeptidases (proline-containing bonds are refractory to most peptidases). Selank is a synthetic analog of the endogenous tuftsin molecule, elongated at the C terminus via the addition of three natural L-amino acids (Pro-Gly-Pro) to improve its metabolic stability and yield a relatively longer duration of action. The resulting heptapeptide retains tuftsin’s pharmacological properties and adds CNS activity from the Pro-Gly-Pro extension, which appears to facilitate blood-brain barrier penetration — particularly relevant for intranasal administration directly to the olfactory epithelium.^[4]

Structure

Full amino acid sequence: Thr¹-Lys²-Pro³-Arg&sup4;-Pro&sup5;-Gly&sup6;-Pro&sup7;. The first four residues (Thr-Lys-Pro-Arg) are the native tuftsin sequence; the C-terminal extension Pro-Gly-Pro provides stability. Molecular weight approximately 751 Da. The molecule is entirely composed of natural L-amino acids, contributing to low immunogenicity and a favourable tolerability profile. As an all-natural-amino-acid peptide of only 7 residues, it degrades to normal amino acid metabolites — no toxic metabolites are anticipated.

Mechanism of Action: Multiple Pathways

Selank’s mechanisms are genuinely complex and reflect the multi-target pharmacology that characterises many neuropeptides. The relative contribution of each pathway to observed clinical effects is not precisely quantified.

1. Enkephalinase inhibition (opioidergic system)

One of the best-documented mechanisms: Selank inhibits enkephalin-degrading enzymes (enkephalinases), increasing the half-life of endogenous enkephalins in the brain. Enkephalins are endogenous opioid peptides that activate delta opioid receptors, producing anxiolytic and mood-elevating effects without the reward/addiction profile of mu-opioid activation. By preventing enkephalin degradation rather than directly activating opioid receptors, Selank enhances endogenous opioidergic tone in a physiologically regulated manner. The 2008 clinical trial (Zozulia et al.) found that GAD/neurasthenia patients had reduced leu-enkephalin half-life at baseline, and Selank treatment normalised this — suggesting the enkephalinase pathway is clinically relevant in the target patient population.^[1]

2. GABAergic modulation

Selank’s anxiolytic effects are similar to those of classical benzodiazepine drugs, which enhance the inhibitory effect of GABA by allosteric modulation of GABA-A receptors — suggesting the molecular mechanism of Selank’s effect may also be related to its ability to affect GABA receptors. Volkova et al. (2016, Frontiers in Pharmacology) found that Selank administration altered mRNA levels of genes involved in GABAergic neurotransmission in rat brain, suggesting transcriptional effects on the GABAergic system.^[4] However, a separate in vitro study found no direct change in GABA-A receptor gene expression in response to Selank alone — only when combined with olanzapine. This suggests Selank’s GABAergic effects may be indirect or require in vivo CNS conditions not replicated in cell culture. The precise receptor-level pharmacology remains incompletely characterised.

3. Serotonin system and monoamines

Selank influences serotonin metabolism — specifically the rate of serotonin turnover in different brain regions. Its cognition-enhancing effects may be due to an ability to influence brain levels of noradrenaline, serotonin, and dopamine, three neurotransmitters with well-documented relationships to vigilance, attention, learning, and motivation. The mechanism is not via direct SERT inhibition (as with SSRIs) but through indirect modulation of serotonin metabolic pathways.^[6]

4. BDNF upregulation

Inozemtseva et al. (2008) demonstrated that intranasal Selank administration rapidly elevates BDNF (brain-derived neurotrophic factor) expression in the rat hippocampus in vivo.^[5] This BDNF upregulation is consistent with Selank’s reported cognitive (nootropic) effects and is a shared feature with the related peptide Semax. Kolik et al. (2019) showed that Selank protected against ethanol-induced memory impairment in rats by regulating BDNF content in the hippocampus and prefrontal cortex, providing a functional link between the BDNF mechanism and memory endpoints.^[7]

5. Immunomodulatory activity (tuftsin heritage)

Selank retains tuftsin’s immunomodulatory properties, including effects on IL-6 expression, T-helper cytokine balance (Th1/Th2 ratio), and macrophage phagocytic activity. Uchakina et al. (2008) documented immunomodulatory effects in patients with anxiety-asthenic disorders.^[3] These immunological effects may contribute to Selank’s anti-asthenic (fatigue-reducing) properties through normalisation of stress-related immune dysregulation.

Russian Regulatory History

Selank was developed at the Institute of Molecular Genetics through research on tuftsin analogues through the 1990s before entering human trials. The Russian Federation Ministry of Health approved it in 2009 as a prescription intranasal formulation for generalised anxiety disorder (GAD) and neurasthenia, marketed in Russia and Ukraine under the brand name Selanc (Ñеланк) as a nasal spray at 0.15% concentration (300 µg/dose). Selank was subsequently placed on the FDA’s Category 2 list in 2023 but removed in September 2024 following additional safety information from the nominator — restoring compounding permissibility in the US with a valid prescription.

Clinical Evidence

The pivotal Russian clinical trial (Zozulia et al., 2008)

Sixty-two patients with GAD and neurasthenia; Selank (N=30) compared to medazepam (N=32). Outcomes assessed with Hamilton, Zung, and CGI scales; leu-enkephalin activity in blood serum measured. The anxiolytic effects of both drugs were similar, but Selank had also antiasthenic and psychostimulant effects — not seen with the benzodiazepine comparator. Biological correlate: GAD/neurasthenia patients had reduced leu-enkephalin half-life, normalised by Selank treatment. Safety: no sedation, no cognitive impairment, no dependence with Selank.^[1]

This trial provides the primary data point for Selank’s anxiolytic efficacy, but it has significant limitations for contemporary Western regulatory standards: N=62, single centre (presumably), published in Russian, no independent replication, no long-term follow-up, and the comparator (medazepam) is not a front-line GAD treatment in contemporary Western practice.

Subsequent comparative trials

Multiple subsequent Russian clinical studies compared Selank to phenazepam (a high-potency benzodiazepine widely used in Russia) and other anxiolytics, with consistent findings of comparable anxiolytic efficacy and superior tolerability for Selank.^[2] These studies share the methodological limitations of the 2008 trial: small samples, single institution, Russian-language publication, no independent replication.

Evidence Summary

Comparison: Selank vs. Benzodiazepines

The superior tolerability profile claimed for Selank relative to benzodiazepines is the central clinical argument for its use. The evidence comes from small Russian trials, not from large head-to-head RCTs that would inform clinical guidelines in Western medicine. The pharmacological rationale for lower dependence/tolerance risk is sound — multiple complementary mechanisms rather than direct GABA-A modulation — but it has not been established at an evidence level that would change clinical practice in the West.

Comparison: Selank vs. Semax

Safety Profile

Russian clinical trials consistently report Selank as highly well-tolerated: no sedation; no cognitive impairment; no dependence; no withdrawal syndrome; no tolerance at trial durations (up to 1 month); no significant cardiovascular, hepatic, or renal effects documented. The most common adverse effects are mild nasal irritation from the intranasal formulation and mild headache.

⚠️ What is not known: Long-term safety beyond the trial durations of 2–4 weeks; safety in pregnancy and breastfeeding; drug-drug interaction profile (particularly with SSRIs, benzodiazepines, other CNS-active drugs); and the safety of subcutaneous injection (the community-preferred route outside Russia), for which no formal pharmacokinetic or safety study exists. Immunomodulatory concern: Selank retains tuftsin’s immunomodulatory properties. In individuals with autoimmune conditions, immune stimulation could theoretically exacerbate disease; this has not been systematically studied.

Regulatory Status

Common Misconceptions

“Selank is a black-market research chemical with no legitimate use.”

Selank is a prescription drug in Russia and Ukraine, approved after regulatory review for GAD and neurasthenia. It has been used clinically for 15+ years. Calling it a black-market chemical misrepresents its regulatory status in the countries where it is approved.

“Selank is basically a peptide version of diazepam.”

Selank does not directly bind GABA-A receptor benzodiazepine sites. The clinical effect profile (anxiolytic without sedation/amnesia/dependence) distinguishes it mechanistically from benzodiazepines, even if the clinical endpoint (anxiety reduction) is comparable in small trials.

“The science is all from Russia so it can’t be trusted.”

Russian pharmacological research is legitimate science. The underlying biology (GABAergic system, enkephalinase, BDNF, serotonin) is well-understood globally. The concern is methodological — small sample sizes, limited independent replication, language barriers — not that Russian science is inherently invalid.

Frequently Asked Questions

Is Selank effective for GAD in Western patients?

Based on the available evidence (primarily the 2008 Russian trial, N=62), Selank produced anxiolytic effects comparable to medazepam without benzodiazepine side effects. This is encouraging but not definitive for Western clinical practice. The trial is too small and methodologically limited to support clinical guidelines. Anecdotal community experience in Western users is broadly consistent with anxiolytic effects, but anecdotal evidence is not a substitute for controlled trials.

Why hasn’t Selank been studied in Western Phase 2/3 trials?

No Western pharmaceutical company has invested in bringing Selank through the Western regulatory process. The compound was developed by Russian academic institutions without the commercial infrastructure for international trials. Without a commercial sponsor willing to fund a Phase 2/3 programme (typically $100M+), the Western regulatory pathway does not progress regardless of the Russian approval.

Can Selank be used long-term?

Russian protocols use Selank in 14-day courses with breaks. Community use often involves similar cycling patterns (2–4 weeks on, 2–4 weeks off). Long-term daily use data does not exist from clinical trials. The absence of tolerance and dependence observed in short-term trials is reassuring but does not establish long-term safety.

Key Takeaways

1. ✅ Selank has more regulatory legitimacy than almost any other compound in the Western community nootropic market. It is approved as a prescription drug in Russia and Ukraine based on clinical trial evidence — a history that distinguishes it from the vast majority of compounds in this series that have never been through any regulatory review.
2. ⚠️ The clinical evidence, while real, is limited by Western standards. The pivotal trial enrolled 62 patients at presumably a single Russian institution, published in Russian, and has not been independently replicated in large multicentre trials. Sufficient for Russian regulatory approval; not sufficient for FDA/EMA approval.
3. The proposed mechanism — anxiolytic without benzodiazepine liabilities — is pharmacologically plausible. Multiple complementary mechanisms (enkephalinase inhibition, indirect GABAergic modulation, serotonin system effects, BDNF upregulation) rather than direct GABA-A agonism are consistent with the observed clinical profile of anxiolytic effects without sedation, amnesia, or dependence.^[1][4]
4. ✅ The FDA Category 2 removal (September 2024) is a positive regulatory development. US compounding pharmacies can legally prepare Selank for patients with valid prescriptions.
5. ⚠️ Safety appears favourable in short-term use but long-term data is absent. 15+ years of clinical use in Russia without major safety signals is reassuring. Chronic use carries uncharacterised risks that short-term clinical observation cannot quantify.

References